CCCC logo

C4 Therapeutics Inc. (CCCC)

$2.65

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CCCC

Market cap

$347991343

EPS

-0.63

P/E ratio

--

Price to sales

11.1

Dividend yield

--

Beta

3.175955

Price on CCCC

Previous close

$2.76

Today's open

$2.72

Day's range

$2.59 - $2.76

52 week range

$1.69 - $5.17

Profile about CCCC

CEO

Andrew J. Hirsch

Employees

104

Headquarters

Watertown, MA

Exchange

Nasdaq Global Select

Shares outstanding

131317488

Issue type

Common Stock

CCCC industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CCCC

C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab; Progressing Additional Cohorts with Data from All Evaluated Cohorts Expected in Mid-2027 Phase 1b Trial of Cemsidomide in Combination with Approved Standard of Care Multiple Myeloma Therapies On Track to Initiate in 1H 2027 WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the third quarter ended September 30, 2026, as well as recent business highlights.

news source

GlobeNewsWire • Nov 5, 2026

news preview

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.44 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

C4 Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in upcoming investor conferences in November.

news source

GlobeNewsWire • Nov 3, 2026

news preview

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on November 2, 2026 (the “Grant Date”).

news source

GlobeNewsWire • Nov 2, 2026

news preview

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today highlighted its novel DNA-encoded library (DEL) that leverages C4T's large library of cereblon-binding ligands and screening capabilities in a presentation at the 9th Annual Targeted Protein Degradation Summit in Boston titled “Target-First Discovery of Molecular Glue Degraders Using DNA-Encoded Libraries.

news source

GlobeNewsWire • Oct 29, 2026

news preview

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Insmed Appoints Two New Directors to Its Board

—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.

news source

PRNewsWire • Oct 20, 2026

news preview

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action

news source

GlobeNewsWire • Sep 25, 2026

news preview

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Sep 23, 2026

news preview

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting.

news source

GlobeNewsWire • Sep 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in C4 Therapeutics Inc.

Open an M1 investment account to buy and sell C4 Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CCCC on M1